COMPOUNDS 563
    3.
    发明申请
    COMPOUNDS 563 失效
    化合物563

    公开(公告)号:US20100130495A1

    公开(公告)日:2010-05-27

    申请号:US12613935

    申请日:2009-11-06

    摘要: The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

    摘要翻译: 本发明涉及式I的新化合物及其治疗上可接受的盐,其药物组合物,其制备方法及其作为治疗和/或预防各种疾病的治疗方法。 特别地,本发明涉及抑制A&bgr 40和A&bgr 42生产的化合物,增加A&bgr 37和A&bgr 38产量并维持Notch信号,并将用于治疗和/或预防A&bgr相关 诸如阿尔茨海默氏病,唐氏综合征和淀粉样血管病的病态,例如但不限于脑淀粉样血管病,遗传性脑出血,与认知障碍相关的病症,例如但不限于MCI(“轻度认知障碍”), 阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与诸如阿尔茨海默病或痴呆的疾病相关的神经变性,包括混合血管和退行性起源的痴呆,老年痴呆,老年痴呆和与帕金森病相关的痴呆,进行性核上性麻痹 或皮质基底变性。